Case Study

Scaling A Solid Tumor Study

Business Meeting

A mid-sized multinational biopharmaceutical company opted to internalize the study management and execution of their Phase Ib/II multicenter oncology program. The original objective was to enroll 120 subjects among 18 sites, across 6 cancer types. The Sponsor chose Catalyst as their clinical monitoring partner to augment their internal team.

As a result of positive treatment outcomes, patients continued in the trial for significantly longer than originally projected, creating a large data backlog that required source document verification. A study that was initially forecasted to complete within 16 months, created both opportunities and challenges for the Sponsor including multiple protocol amendments, expansion of study centers into Europe, and expanding patient enrollment three-fold in specific tumor types. The initial CRA monitoring team needed to scale to meet the realities of this high priority program.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: